BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
Published . Updated .
In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma raised its full-year revenue forecast.
Directly affected
- BMY Bristol Myers Squibb-3.5% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story.
- LLY Eli Lilly and+12.0% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.4% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
- PFE Pfizer+6.7% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
- MRK Merck-2.6% 16d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| BMYNo price data for this ticker | — | — | — | — | — | — | — |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| XBINo price data for this ticker | — | — | — | — | — | — | — |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| PFENo price data for this ticker | — | — | — | — | — | — | — |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat BioSpace
Source: BioSpace
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 34 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 51 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 69 days before publication. Filed 8 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 31 Jul 2026. That is 90 days before publication. Filed 22 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 71 days before publication. Filed 9 Sep 2026. View the filing.
- Donald J Trump, an executive branch official, sold Merck (MRK), worth $250,001 - $500,000 on 31 Jul 2026. That is 90 days before publication. Filed 22 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies tied to this story
- XLV Select Sector Spdr Tr
In “BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story
- XBI Spdr Series Trust
In “BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story
- LLY Eli Lilly
Eli Lilly (LLY) is linked, with no stored direction, medium confidence in the 29 Oct 2026 story “BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat.” Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story
- JNJ Johnson & Johnson
In “BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 29 Oct 2026 story “BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story
- MRK Merck
Merck (MRK) is linked, with no stored direction, medium confidence in the 29 Oct 2026 story “BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat.” Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
On 29 Oct 2026, “BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat” is the story that connects Select Sector Spdr Tr (XLV) to this story.
What ties Select Sector Spdr Tr (XLV) to the headline is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1131.55 and 1321.17 across 20 sessions. The latest close on file is 1290.65. XBI traded between 152.63 and 157.39 across 1 sessions. The latest close on file is 154.01. XLV traded between 166.19 and 168.02 across 1 sessions. The latest close on file is 167.68.
A simple score for Select Sector Spdr Tr (XLV)
46 out of 100
“BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.